Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase Ia/Ib trial of GM-3009

Next Previous
Search
Trial Profile

A phase Ia/Ib trial of GM-3009

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 25 Mar 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GM 3009 (Primary)
  • Indications Opioid-related disorders
  • Focus Adverse reactions

    • Most Recent Events

    • 25 Mar 2024 New trial record
    • 14 Mar 2024 According to a Gilgamesh Pharmaceuticals media release, the company has been awarded a multi-year $14 million grant from the National Institute on Drug Abuse (NIDA) to develop GM-3009. This grant provides non-dilutive funding to support IND-enabling toxicology studies, GMP manufacturing, and Phase 1/1b clinical trials. Following completion of the funded development, GM-3009 will be ready to enter larger Phase 2 efficacy studies.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top